Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.

Takase T, Nakamura A, Yamamoto C, Nomoto H, Miya A, Dannoura M, Cho KY, Kurihara Y, Manda N, Aoki S, Atsumi T, Miyoshi H

Journal of diabetes investigation19 Sept 2018Cited by 33 (Europe PMC)

PMID30076787PMCIDPMC6497607DOI10.1111/jdi.12906PepBankPUB-30076787

Read at source PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, the change in treatment satisfaction score was smaller with continued daily liraglutide than with a switch to weekly dulaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, treatment satisfaction improved less with continued liraglutide than with a switch to weekly dulaglutide.
Peptide
Liraglutide
Outcome
DecreaseChange in Diabetes Treatment Satisfaction Questionnaire score
Study
n = 31
Comparator
Dulaglutide once weekly
Analysis
Primary
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
The change in the Diabetes Treatment Satisfaction Questionnaire score in the Dula group was significantly greater than that in the Lira group (+0.1 ± 4.7 in the Lira group vs +4.9 ± 5.2 in the Dula group; P = 0.013).
2 context sentences(design, population, supporting numbers)
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
Report a problemFND-3007678701
02HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, the change in therapy-related quality of life score was lower with continued daily liraglutide (-3.7) than with a switch to weekly dulaglutide (+8.9).
In plain wordsIn Japanese adults with type 2 diabetes, the quality of life score fell with continued liraglutide but rose after a switch to weekly dulaglutide.
Peptide
Liraglutide
Outcome
DecreaseChange in Diabetes Therapy-Related Quality of Life score
Study
n = 31
Comparator
Dulaglutide once weekly
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
The change in Diabetes Therapy-Related Quality of Life score in the Dula group was significantly greater than that in the Lira group (-3.7 ± 6.9 vs +8.9 ± 15.1; P = 0.007).
2 context sentences(design, population, supporting numbers)
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
Report a problemFND-3007678702
03HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, change in body mass did not differ between continued liraglutide and switching to dulaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, body mass change did not differ between continuing liraglutide and switching to dulaglutide.
Peptide
Liraglutide
Outcome
No significant changeChange in body mass
Study
n = 31
Comparator
Dulaglutide once weekly
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin.
2 context sentences(design, population, supporting numbers)
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
Report a problemFND-3007678703
04HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, change in plasma glucose did not differ between continued liraglutide and switching to dulaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, blood glucose change did not differ between continuing liraglutide and switching to dulaglutide.
Peptide
Liraglutide
Outcome
No significant changeChange in plasma glucose
Study
n = 31
Comparator
Dulaglutide once weekly
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin.
2 context sentences(design, population, supporting numbers)
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
Report a problemFND-3007678704
05HumanRandomized controlled trialEfficacy outcome
In Japanese patients with type 2 diabetes, change in glycated hemoglobin did not differ between continued liraglutide and switching to dulaglutide.
In plain wordsIn Japanese adults with type 2 diabetes, HbA1c change did not differ between continuing liraglutide and switching to dulaglutide.
Peptide
Liraglutide
Outcome
No significant changeChange in glycated hemoglobin
Study
n = 31
Comparator
Dulaglutide once weekly
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin.
2 context sentences(design, population, supporting numbers)
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
Report a problemFND-3007678705
06HumanRandomized controlled trialEfficacy outcome
In Japanese patients with diabetes, body mass changes did not differ significantly between dulaglutide and liraglutide.
In plain wordsIn Japanese patients with diabetes, body mass changes did not differ significantly between dulaglutide and liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBody mass
Study
n = 31
Comparator
Continued daily liraglutide
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 12-week, multicenter, open-label, prospective, randomized, parallel-group comparison trial.
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
Report a problemFND-3007678708
07HumanRandomized controlled trialEfficacy outcome
In Japanese patients with diabetes, plasma glucose changes did not differ significantly between dulaglutide and liraglutide.
In plain wordsIn Japanese patients with diabetes, blood glucose changes did not differ significantly between dulaglutide and liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePlasma glucose
Study
n = 31
Comparator
Continued daily liraglutide
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 12-week, multicenter, open-label, prospective, randomized, parallel-group comparison trial.
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
Report a problemFND-3007678709
08HumanRandomized controlled trialEfficacy outcome
In Japanese patients with diabetes, glycated hemoglobin changes did not differ significantly between dulaglutide and liraglutide.
In plain wordsIn Japanese patients with diabetes, HbA1c changes did not differ significantly between dulaglutide and liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeGlycated hemoglobin
Study
n = 31
Comparator
Continued daily liraglutide
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 12-week, multicenter, open-label, prospective, randomized, parallel-group comparison trial.
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
Report a problemFND-3007678710

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

09HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In Japanese patients with diabetes, switching to weekly dulaglutide improved treatment satisfaction more than continuing daily liraglutide.
In plain wordsIn Japanese patients with diabetes, switching to weekly dulaglutide improved treatment satisfaction more than continuing daily liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseTreatment satisfaction
Study
n = 31
Comparator
Continued daily liraglutide
Analysis
Primary
Outcome group
Patient-reported outcomes · Whole body
Measurements
Change in DTSQ score
0.1 score
Lira group, ± 4.7
Change in DTSQ score
4.9 score
Dula group, ± 5.2
Source sentences
Summary
The change in the Diabetes Treatment Satisfaction Questionnaire score in the Dula group was significantly greater than that in the Lira group (+0.1 ± 4.7 in the Lira group vs +4.9 ± 5.2 in the Dula group; P = 0.013).
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 12-week, multicenter, open-label, prospective, randomized, parallel-group comparison trial.
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3007678706
10HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In Japanese patients with diabetes, switching to weekly dulaglutide improved therapy-related quality of life more than continuing daily liraglutide.
In plain wordsIn Japanese patients with diabetes, switching to weekly dulaglutide improved quality of life more than continuing daily liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseTherapy-related quality of life
Study
n = 31
Comparator
Continued daily liraglutide
Analysis
Secondary
Outcome group
Quality of life · Whole body
Measurements
Change in DTR-QOL score
−3.7 score
Lira group, ± 6.9 (group assigned from 'Dula greater than Lira' wording)
Change in DTR-QOL score
8.9 score
Dula group, ± 15.1 (group assigned from 'Dula greater than Lira' wording)
Source sentences
Summary
The change in Diabetes Therapy-Related Quality of Life score in the Dula group was significantly greater than that in the Lira group (-3.7 ± 6.9 vs +8.9 ± 15.1; P = 0.007).
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 12-week, multicenter, open-label, prospective, randomized, parallel-group comparison trial.
Summary · context
The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months.
Summary · context
Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3007678707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.

Summary

Results from this study10

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

MeSH terms

Keywords